![Wolfgang Hartwig](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Wolfgang Hartwig
Directeur Général chez Pharma R&D Consulting GmbH
Provenance du réseau au premier degré de Wolfgang Hartwig
Entité | Type d'entité | Industrie | |
---|---|---|---|
Xention Pharma Ltd.
![]() Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Public Company | Chemicals: Specialty | 4 | |
University of Münster
3
| College/University | Other Consumer Services | 3 |
URBANA Energiedienste GmbH
![]() URBANA Energiedienste GmbH Electric UtilitiesUtilities URBANA Energiedienste GmbH operates as an energy service provider. The firm's services include efficiency deals, energy plans, EcoQuartier management, current gantries and performance processes. The company was founded in 1963 and is headquartered in Hamburg, Germany.
2
| Subsidiary | Electric Utilities | 2 |
LTS LOHMANN Therapie-Systeme AG
![]() LTS LOHMANN Therapie-Systeme AG Pharmaceuticals: MajorHealth Technology LTS LOHMANN Therapie-Systeme AG manufactures transdermal therapeutic systems and oral thin films. The firm's product range encompasses oral active ingredient films, nicotine patches, and pharmaceutical drugs in dosage forms. Its service areas cover clinical trials, laboratory testing, and research and development projects. The company was founded in 1984 and is headquartered in Andernach, Germany.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Wolfgang Hartwig via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Alantos Pharmaceuticals Holding, Inc.
![]() Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Director/Board Member | |
BioVex, Inc.
![]() BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Director/Board Member | |
BioVex Group, Inc.
![]() BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Director/Board Member | |
Forbion Co-Investment II Coöperatief UA
![]() Forbion Co-Investment II Coöperatief UA Investment ManagersFinance Part of Forbion Capital Partners Management Holding BV, the venture capital firm, Forbion Co-Investment II Coöperatief UA, is based in Naarden, Netherlands. Forbion Co-Investment II Coöperatief UA operates as a venture capital firm. The Dutch company was founded in 2000 by Bart Bergstein, Hugo Alexander Slootweg, Martien van Osch. | Investment Managers | Founder | |
DEUTSCHE EUROSHOP AG | Real Estate Development | Director/Board Member | |
ENCAVIS AG | Electric Utilities | Director/Board Member | |
University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
Pulmagen Therapeutics (Synergy) Ltd.
![]() Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
University of Bristol | College/University | Undergraduate Degree Undergraduate Degree | |
Shell Deutschland GmbH
![]() Shell Deutschland GmbH Wholesale DistributorsDistribution Services Shell Deutschland Oil GmbH operates gas stations. Their business activities encompass oil and petroleum distribution, commercial fuel trading and energy investments. The company is based in Hamburg, Germany. | Wholesale Distributors | President | |
University of Amsterdam | College/University | Undergraduate Degree | |
Roche Glycart AG
![]() Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Vrije Universiteit Amsterdam | College/University | Undergraduate Degree | |
Johann Wolfgang Goethe-Universität Frankfurt am Main | College/University | Doctorate Degree | |
Kernel Management Partners Ltd.
![]() Kernel Management Partners Ltd. Investment ManagersFinance Kernel Management Partners Ltd. (Kernel Capital) is a venture capital firm founded in 1999 by Niall Olden. The firm is headquartered in Cork, Ireland. | Investment Managers | Private Equity Investor | |
Biosensia Ltd.
![]() Biosensia Ltd. Packaged SoftwareTechnology Services Biosensia Ltd. develops multiplexing point of care in vitro diagnostics platform. It offers RapiPlex, a point-of-care diagnosis system based on a set of proprietary technologies capable of producing quantitative and qualitative laboratory quality test results. The company was founded by Gareth Redmond and Gabriel Crean in 2009 and is headquartered in Dublin, Ireland. | Packaged Software | Director/Board Member | |
Oxyrane UK Ltd.
![]() Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Kreke Immobilien KG
![]() Kreke Immobilien KG Medical/Nursing ServicesHealth Services Kreke Immobilien KG operates as a holding company with interest in providing apartments, residences, and also for renting purpose. The company is headquartered in Hagen, Germany | Medical/Nursing Services | Chairman | |
Crescent Diagnostics Ltd.
![]() Crescent Diagnostics Ltd. Medical/Nursing ServicesHealth Services Crescent Diagnostics Ltd. operates as a medical diagnostics company. The firm offers bone quality test, an osteoporosis screening tool that enables clinicians to identify those who are at high risk of suffering a hip fracture. The company was founded by Mark Towler and Ernest Poku in 2004 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
Dassiet Oy
![]() Dassiet Oy Medical SpecialtiesHealth Technology Onbone Oy develops medical casting and splinting materials for use in the fields of orthopaedics, traumatology and occupational therapy. The company was founded by Petro Antero Kirmo Lahtinen, Antti Pärssinen, Jari Juhani Salo, Matti Eino Olavi Vaheri, and Karri Airola on November 18, 2008 and is headquartered in Oulu, Finland. | Medical Specialties | Director/Board Member | |
Pulmagen Therapeutics LLP
![]() Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Xention Ltd.
![]() Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Seroba BioVentures Ltd.
![]() Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | Investment Managers | Private Equity Investor Private Equity Investor | |
UNIQURE N.V. | Biotechnology | Director/Board Member | |
MVM Gp (No.3) Scottish LP | Director/Board Member | ||
VALNEVA | Biotechnology | Director/Board Member | |
REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member | |
yaska Kalorimeta GmbH
![]() yaska Kalorimeta GmbH Real Estate DevelopmentFinance Yaska Kalorimeta GmbH is a German company that buys and sells real estate properties. The private company is based in Grunwald, Germany. The CEOs of the company are Henning R. Kreke, Jacqueline Hinderer. | Real Estate Development | Chief Executive Officer | |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member | |
Oxyrane, Ltd. | Director/Board Member | ||
Azafaros BV
![]() Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Impella Cardiosystems AG
![]() Impella Cardiosystems AG Medical SpecialtiesHealth Technology Impella Cardiosystems AG develops, manufactures, and markets minimally invasive cardiovascular support systems. The company is based in Aachen, Germany. The German company was founded by Thorsten Sieß. | Medical Specialties | Director/Board Member | |
Amt NV | Chairman | ||
NewAmsterdam Pharma Holding BV
![]() NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Chairman | |
VectorY BV
![]() VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
NewAmsterdam Pharma BV
![]() NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Chairman | |
Patient Connect Ltd.
![]() Patient Connect Ltd. Medical/Nursing ServicesHealth Services Patient Connect Ltd. provides supporting services for patients at the point of dispensing. It operates a community where pharmacists provide medicines to help patients. The firm offers patient compliance services. The company was founded by Grace Lomax and Zoe Barker in 2004 and is headquartered in Guildford, the United Kingdom. | Medical/Nursing Services | Chairman |
Statistiques
Internationale
Royaume-Uni | 15 |
Allemagne | 11 |
Pays-Bas | 10 |
Etats-Unis | 9 |
Irlande | 4 |
Sectorielle
Health Technology | 23 |
Finance | 8 |
Consumer Services | 6 |
Health Services | 4 |
Retail Trade | 3 |
Opérationnelle
Director/Board Member | 115 |
Corporate Officer/Principal | 27 |
Chairman | 20 |
Independent Dir/Board Member | 10 |
Private Equity Investor | 9 |
Relations les plus connectées
- Bourse
- Insiders
- Wolfgang Hartwig
- Connexions Sociétés